Genomeditech (Shanghai) Co.,Ltd.
Order: +86 021-68455258/50432826/50432825
Toll-free: +86 400 627 9288
Email: service@genomeditech.com

# Product Sheet

## H_MRGPRX2 CHO-K1 Cell Line

Catalog number: GM-C38751

Version 3.3.1.250228

| | |
|---|---|
| **Description** | H_MRGPRX2 CHO-K1 Cell Line is a clonal stable CHO-K1 cell line that constitutively expresses the human MRGPRX2 gene, constructed using lentiviral technology. |
| **Quantity** | 5E6 Cells per vial,1 mL |
| **Product Format** | 1 vial of frozen cells |
| **Shipping** | Shipped on dry ice |
| **Storage Conditions** | Liquid nitrogen immediately upon receipt |

| | |
|---|---|
| **Target** | Human_MRGPRX2 |
| **Gene ID/Uniprot ID** | Q96LB1 |
| **Host Cell** | CHO-K1 |

| | |
|---|---|
| **Recovery Medium** | F12K+10% FBS+1% P.S |
| **Growth medium** | F12K+10% FBS+1% P.S+4 μg/mL Puromycin |
| **Note** | None |
| **Freezing Medium** | 90% FBS+10% DMSO |
| **Growth properties** | Adherent |
| **Growth Conditions** | 37°C, 5% $CO_2$ |

| | |
|---|---|
| **Mycoplasma Testing** | The cell line has been screened to confirm the absence of Mycoplasma species. |
| **Safety considerations** | Biosafety Level 2 |
| **Note** | It is recommended to expand the cell culture and store a minimum of 10 vials at an early passage for potential future use. |

Genomeditech (Shanghai) Co.,Ltd.
Order: +86 021-68455258/50432826/50432825
Toll-free: +86 400 627 9288
Email: service@genomeditech.com

## Materials

| Reagent | Manufacturer/Catalogue No. |
|---|---|
| F12K | BOSTER/PYG0036 |
| Fetal Bovine Serum | Cegrogen biotech/A0500-3010 |
| Pen/Strep | Thermo/15140-122 |
| Puromycin | Genomeditech/GM-040401 |
| APC anti-human MRGX2 Antibody | Biolegend/359006 |

## Figures




| SampleID | Geometric Mean : FL11-H |
|---|---|
| CHO-K1 APC-anti-MRGX2 Ab | 1261 |
| CHO-K1 H_MRGPRX2 APC-M_IgG Ab | 1745 |
| CHO-K1 H_MRGPRX2 APC-anti-MRGX2 Ab | 289601 |

Figure 1 | H_MRGPRX2 CHO-K1 Cell Line (Cat. GM-C38751) was determined by flow cytometry using APC anti-human MRGX2 Antibody (Biolegend/359006).




| SampleID | Geometric Mean : FL11-H |
|---|---|
| CHO-K1 APC-anti-MRGX2 Ab | 2221 |
| CHO-K1 H_MRGPRX2 APC-M_IgG Ab | 1483 |
| CHO-K1 H_MRGPRX2 APC-anti-MRGX2 Ab CP4 | 291424 |
| CHO-K1 H_MRGPRX2 APC-anti-MRGX2 Ab CP15 | 269232 |
| CHO-K1 H_MRGPRX2 APC-anti-MRGX2 Ab CP24 | 261050 |

Figure 2 | The passage stability of the H_MRGPRX2 CHO-K1 Cell Line (Cat. GM-C38751) was determined by flow cytometry using APC anti-human MRGX2 Antibody (Biolegend/359006).

Genomeditech (Shanghai) Co.,Ltd.
Order: +86 021-68455258/50432826/50432825
Toll-free: +86 400 627 9288
Email: service@genomeditech.com

## Cell Recovery

Recovery Medium: F12K+10% FBS+1% P.S

To insure the highest level of viability, thaw the vial and initiate the culture as soon as possible upon receipt. If upon arrival, continued storage of the frozen culture is necessary, it should be stored in liquid nitrogen vapor phase and not at -70°C. Storage at -70°C will result in loss of viability.

a) Thaw the vial by gentle agitation in a 37°C water bath. To reduce the possibility of contamination, keep the O-ring and cap out of the water. Thawing should be rapid (approximately 2 - 3 minutes).
b) Remove the vial from the water bath as soon as the contents are thawed, and decontaminate by dipping in or spraying with 70% ethanol. All of the operations from this point on should be carried out under strict aseptic conditions.
c) Transfer the vial contents to a centrifuge tube containing 5.0 mL complete culture medium and spin at approximately 176 x g for 5 minutes. Discard supernatant.
d) Resuspend cell pellet with the recommended recovery medium. And dispense into appropriate culture dishes.
e) Incubate the culture at 37°C in a suitable incubator. A 5% $CO_2$ in air atmosphere is recommended if using the medium described on this product sheet.

## Cell Freezing

Freezing Medium: 90% FBS+10% DMSO

a) Centrifuge at 176 x g for 3 minutes to collect cells.
b) Resuspend the cells in pre-cooled freezing medium and adjust the cell density to 5E6 cells/mL.
c) Aliquot 1 mL into each vial.
d) Place the vial in a controlled-rate freezing container and store at -80°C for at least 1 day, then transfer to liquid nitrogen as soon as possible.

## Cell passage

Growth medium: F12K+10% FBS+1% P.S+4 μg/mL Puromycin

For the first 1 to 2 passages post-resuscitation, use the recovery medium. Once the cells have stabilized, switch to a growth medium.

a) Remove and discard culture medium.
b) Briefly rinse the cell layer with PBS to remove all traces of serum that contains trypsin inhibitor.
c) Add 1.0 mL of 0.25% (w/v) Trypsin-EDTA solution to dish and observe cells under an inverted microscope until cell layer is dispersed (usually within 2 to 3 minutes at 37°C).
d) Note: To avoid clumping do not agitate the cells by hitting or shaking the flask while waiting for the cells to detach. Cells that are difficult to detach may be placed at 37°C to facilitate dispersal.
e) Add 2.0 mL of growth medium to mix well and aspirate cells by gently pipetting.
f) After centrifugation, resuspend the pellet and add appropriate aliquots of the cell suspension to new culture vessels.
g) Incubate cultures at 37°C.

**Subcultivation Ratio: A subcultivation ratio of 1:4 - 1:5 is recommended**

**Medium Renewal: Every 2 to 3 days**

## Notes

a) After the stabilization of the cell condition, there will be fewer dead cells post-passage, the cell growth rate will tend to stabilize, cell morphology will become uniform, and the cells will appear robust.

## Sequence

MRGPRX2 Q96LB1

MDPTTPAWGTESTTVNGNDQALLLLCGKETLIPVFLILFIALVGLVGNGFVLWLLGFRMRRNAFSVYVLSLA
GADFLFLCFQIINCLVYLSNFFCSISINFPSFFTTVMTCAYLAGLSMLSTVSTERCLSVLWPIWYRCRRPRHLSA
VVCVLLWALSLLLSILEGKFCGFLFSDGDSGWCQTFDFITAAWLIFLFMVLCGSSLALLVRILCGSRGLPLTRL
YLTILLTVLVFLLCGLPFGIQWFLILWIWKDSDVLFCHIHPVSVVLSSLNSSANPIIYFFVGSFRKQWRLQQPIL
KLALQRALQDIAEVDHSEGCFRQGTPEMSRSSLV*

## Related Products

| | |
|---|---|
| OX40 | |
| H_OX40 Reporter Cell Line | Cynomolgus_OX40L CHO-K1 Cell Line |
| H_OX40 CHO-K1 Cell Line | H_OX40L CHO-K1 Cell Line |
| H_OX40L HEK-293 Cell Line | |
| Anti-H_OX40 hIgG2 Antibody(Ivuxolimab) | Anti-OX40L hIgG1 Reference Antibody(Oxebio) |
| Anti-OX40L hIgG4 Antibody(Amlitelimab) | Anti-OX40L hIgG4 Reference Antibody(Amlbio) |
| Biotinylated Human OX40L Protein; His-Avi Tag | Cynomolgus OX40 Protein; His Tag |
| Cynomolgus OX40L Protein; His Tag | Cynomolgus OX40L Protein; mFc Tag |
| Human OX40 Protein; His Tag | Human OX40L Protein; His Tag |
| Human OX40L Protein; mFc Tag | |
| IL-4/IL-13 | |
| IL-4 Reporter Cell Line | IL-4/IL-13 Reporter 293 Cell Line |
| IL-4/IL-13 Reporter 293 DDX35TM Cell Line | Cynomolgus_IL4R CHO-K1 Cell Line |
| H_IL4R CHO-K1 Cell Line | |
| Anti-IL-4R hIgG1 Antibody(12B5) | Anti-IL4R hIgG4 Antibody(Dupilumab) |
| Anti-IL4R hIgG4 Reference Antibody (Dupbio) | |
| Human IL-4R alpha Protein; mFc Tag | |
| IL-31 | |
| Cynomolgus_IL-31RA OSMR Reporter Baf3 Cell Line | H_IL-31 Reporter Cell Line |
| Cynomolgus_IL31RA CHO-K1 Cell Line | H_IL31RA CHO-K1 Cell Line |
| H_IL31RA HEK-293 Cell Line | H_IL-31RA OSMR Baf3 Cell Line |
| Anti-IL31 hIgG1 Antibody(mAb33) | Anti-IL31RA hIgG1 Antibody(NA633) |
| Anti-IL31RA hIgG2 Antibody(Nemolizumab) | Anti-OSMR hIgG4 Antibody(Vixarelimab) |
| c-Kit：SCF | |

| | |
|---|---|
| H_c-Kit(CD117) GNNK(-) 293 Blockade Reporter Cell Line | Cynomolgus_c-Kit(CD117) GNNK(-) CHO-K1 Cell Line |
| H_c-Kit(CD117) GNNK(-) CHO-K1 Cell Line | H_c-Kit(CD117) GNNK(-) HEK-293 Cell Line |
| H_c-Kit(CD117) GNNK(+) CHO-K1 Cell Line | |
| Anti-c-Kit(CD117) hIgG1 Antibody(barzolvolimab) | Anti-c-Kit(CD117) hIgG1 Antibody(briquilimab) |
| Anti-c-Kit(CD117) hIgG1 Reference Antibody(barbio) | |
| Biotinylated Human SCF Protein; His-Avi Tag | Cynomolgus c-Kit(CD117) Protein; His Tag |
| Human c-Kit(CD117) Protein; hFc Tag | Human c-Kit(CD117) Protein; His Tag |
| Human SCF Protein; His Tag | Human SCF Protein; mFc Tag |
| MRGPRX2 | |
| H_MRGPRX2 Reporter Cell Line | H_MRGPRX2 HEK-293 Cell Line |
| Cynomolgus_MRGPRX2 CHO-K1 Cell Line | Cynomolgus_MRGPRX2 HEK-293 Cell Line |

## Limited Use License Agreement

Genomeditech (Shanghai) Co., Ltd grants to the Licensee all intellectual property rights, exclusive, non-transferable, and non-sublicensable rights of the Licensed Materials; Genomeditech (Shanghai) Co., Ltd will retain ownership of the Licensed Materials, cell line history packages, progeny, and the Licensed Materials including modified materials.

Between Genomeditech (Shanghai) Co., Ltd, and Licensee, Licensee is not permitted to modify cell lines in any way. The Licensee shall not share, distribute, sell, sublicense, or otherwise provide the Licensed Materials, or progenitors to third parties such as laboratories, departments, research institutions, hospitals, universities, or biotechnology companies for use other than for the purpose of outsourcing the Licensee's research.

Please refer to the Genomeditech Cell Line License Agreement for details.